In ischemic mouse models, exposure to CD47-blocking agents results in significant improvement of tissue survival and decreased vasculopathy, an evidence of the therapeutic value of CD47 suppression to treat cardiovascular disease [122]. This evidence concerns the gene CD47 and cardiovascular disorder.